Abzena PLC Notice of Full Year Results (1972F)

TIDMABZA

RNS Number : 1972F

Abzena PLC

16 May 2017

Abzena plc

Notice of full year results

Cambridge, UK, 16 May 2017 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full year results for the year to 31 March 2017 on Tuesday, 13 June 2017.

A presentation for analysts will be held at 09:30am on 13 June 2017 at the offices of Instinctif Partners (65 Gresham Street, London EC2V 7NQ).

-Ends-

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive 
    Officer Julian Smith, Chief 
    Financial Officer                  [phone] 
   Numis (Nominated Adviser and 
    Broker) 
    Clare Terlouw / James Black        [phone] 
    / Paul Gillam                       1000 
   N+1 Singer (Joint Broker)           [phone] 
    Aubrey Powell / Liz Yong            3000 
   Instinctif Partners                 [phone] 
    Melanie Toyne Sewell / Alex         2020 
    Shaw / Deborah Bell                 [e-mail] 
 

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'Abzena Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'Abzena Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

   --      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --      Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

   --      GMP manufacturer of ADC linkers, payloads & combined linker-payloads. 

For more information, please see www.abzena.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORGMGMKNKGGNZM

(END) Dow Jones Newswires

May 16, 2017 02:01 ET (06:01 GMT)